Interrogating open issues in cancer precision medicine with patient-derived xenografts

Annette T Byrne; Denis G Alférez; Frédéric Amant; Daniela Annibali; Joaquín Arribas; Andrew V Biankin; Alejandra Bruna; Eva Budinská; Carlos Caldas; David K Chang; Robert B Clarke; Hans Clevers; George Coukos; Virginie Dangles-Marie; S Gail Eckhardt; Eva Gonzalez-Suarez; Els Hermans; Manuel Hidalgo; Monika A Jarzabek; Steven de Jong; Jos Jonkers; Kristel Kemper; Luisa Lanfrancone; Gunhild Mari Mælandsmo; Elisabetta Marangoni; Jean-Christophe Marine; Enzo Medico; Jens Henrik Norum; Héctor G Palmer; Daniel S Peeper; Pier Giuseppe Pelicci; Alejandro Piris-Gimenez; Sergio Roman-Roman; Oscar M Rueda; Joan Seoane; Violeta Serra; Laura Soucek; Dominique Vanhecke; Alberto Villanueva; Emilie Vinolo; Andrea Bertotti; Livio Trusolino

doi:10.1038/nrc.2016.140

Interrogating open issues in cancer precision medicine with patient-derived xenografts

Annette T Byrne, Denis G Alférez, Frédéric Amant, Daniela Annibali, Joaquín Arribas, Andrew V Biankin, Alejandra Bruna, Eva Budinská, Carlos Caldas, David K Chang, Robert B Clarke, Hans Clevers, George Coukos, Virginie Dangles-Marie, S Gail Eckhardt, Eva Gonzalez-Suarez, Els Hermans, Manuel Hidalgo, Monika A Jarzabek, Steven de JongJos Jonkers, Kristel Kemper, Luisa Lanfrancone, Gunhild Mari Mælandsmo, Elisabetta Marangoni, Jean-Christophe Marine, Enzo Medico, Jens Henrik Norum, Héctor G Palmer, Daniel S Peeper, Pier Giuseppe Pelicci, Alejandro Piris-Gimenez, Sergio Roman-Roman, Oscar M Rueda, Joan Seoane, Violeta Serra, Laura Soucek, Dominique Vanhecke, Alberto Villanueva, Emilie Vinolo, Andrea Bertotti, Livio Trusolino

Hubrecht Institute

Onderzoeksoutput: Bijdrage aan wetenschappelijk tijdschrift/periodieke uitgave › Artikel › Wetenschappelijk › peer review

533 Citaten (Scopus)

Samenvatting

Patient-derived xenografts (PDXs) have emerged as an important platform to elucidate new treatments and biomarkers in oncology. PDX models are used to address clinically relevant questions, including the contribution of tumour heterogeneity to therapeutic responsiveness, the patterns of cancer evolutionary dynamics during tumour progression and under drug pressure, and the mechanisms of resistance to treatment. The ability of PDX models to predict clinical outcomes is being improved through mouse humanization strategies and the implementation of co-clinical trials, within which patients and PDXs reciprocally inform therapeutic decisions. This Opinion article discusses aspects of PDX modelling that are relevant to these questions and highlights the merits of shared PDX resources to advance cancer medicine from the perspective of EurOPDX, an international initiative devoted to PDX-based research.

Originele taal-2	Engels
Pagina's (van-tot)	254-268
Aantal pagina's	15
Tijdschrift	Nature reviews. Cancer
Volume	17
Nummer van het tijdschrift	4
DOI's	https://doi.org/10.1038/nrc.2016.140
Status	Gepubliceerd - apr. 2017

Toegang tot document

10.1038/nrc.2016.140

Citeer dit

Byrne, A. T., Alférez, D. G., Amant, F., Annibali, D., Arribas, J., Biankin, A. V., Bruna, A., Budinská, E., Caldas, C., Chang, D. K., Clarke, R. B., Clevers, H., Coukos, G., Dangles-Marie, V., Eckhardt, S. G., Gonzalez-Suarez, E., Hermans, E., Hidalgo, M., Jarzabek, M. A., ... Trusolino, L. (2017). Interrogating open issues in cancer precision medicine with patient-derived xenografts. Nature reviews. Cancer, 17(4), 254-268. https://doi.org/10.1038/nrc.2016.140

@article{16bfb9b59f024c6b9b5381bc13ff3bf7,

title = "Interrogating open issues in cancer precision medicine with patient-derived xenografts",

abstract = "Patient-derived xenografts (PDXs) have emerged as an important platform to elucidate new treatments and biomarkers in oncology. PDX models are used to address clinically relevant questions, including the contribution of tumour heterogeneity to therapeutic responsiveness, the patterns of cancer evolutionary dynamics during tumour progression and under drug pressure, and the mechanisms of resistance to treatment. The ability of PDX models to predict clinical outcomes is being improved through mouse humanization strategies and the implementation of co-clinical trials, within which patients and PDXs reciprocally inform therapeutic decisions. This Opinion article discusses aspects of PDX modelling that are relevant to these questions and highlights the merits of shared PDX resources to advance cancer medicine from the perspective of EurOPDX, an international initiative devoted to PDX-based research.",

keywords = "Animals, Biomarkers, Tumor, Clinical Trials as Topic, Disease Models, Animal, Drug Resistance, Neoplasm, Humans, Immunotherapy, Mice, Neoplasm Metastasis, Neoplasms, Neoplastic Stem Cells, Precision Medicine, Xenograft Model Antitumor Assays, Journal Article, Review, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Extramural",

author = "Byrne, {Annette T} and Alf{\'e}rez, {Denis G} and Fr{\'e}d{\'e}ric Amant and Daniela Annibali and Joaqu{\'i}n Arribas and Biankin, {Andrew V} and Alejandra Bruna and Eva Budinsk{\'a} and Carlos Caldas and Chang, {David K} and Clarke, {Robert B} and Hans Clevers and George Coukos and Virginie Dangles-Marie and Eckhardt, {S Gail} and Eva Gonzalez-Suarez and Els Hermans and Manuel Hidalgo and Jarzabek, {Monika A} and {de Jong}, Steven and Jos Jonkers and Kristel Kemper and Luisa Lanfrancone and M{\ae}landsmo, {Gunhild Mari} and Elisabetta Marangoni and Jean-Christophe Marine and Enzo Medico and Norum, {Jens Henrik} and Palmer, {H{\'e}ctor G} and Peeper, {Daniel S} and Pelicci, {Pier Giuseppe} and Alejandro Piris-Gimenez and Sergio Roman-Roman and Rueda, {Oscar M} and Joan Seoane and Violeta Serra and Laura Soucek and Dominique Vanhecke and Alberto Villanueva and Emilie Vinolo and Andrea Bertotti and Livio Trusolino",

year = "2017",

month = apr,

doi = "10.1038/nrc.2016.140",

language = "English",

volume = "17",

pages = "254--268",

journal = "Nature reviews. Cancer",

issn = "1474-175X",

publisher = "Nature Publishing Group",

number = "4",

}

Byrne, AT, Alférez, DG, Amant, F, Annibali, D, Arribas, J, Biankin, AV, Bruna, A, Budinská, E, Caldas, C, Chang, DK, Clarke, RB, Clevers, H, Coukos, G, Dangles-Marie, V, Eckhardt, SG, Gonzalez-Suarez, E, Hermans, E, Hidalgo, M, Jarzabek, MA, de Jong, S, Jonkers, J, Kemper, K, Lanfrancone, L, Mælandsmo, GM, Marangoni, E, Marine, J-C, Medico, E, Norum, JH, Palmer, HG, Peeper, DS, Pelicci, PG, Piris-Gimenez, A, Roman-Roman, S, Rueda, OM, Seoane, J, Serra, V, Soucek, L, Vanhecke, D, Villanueva, A, Vinolo, E, Bertotti, A & Trusolino, L 2017, 'Interrogating open issues in cancer precision medicine with patient-derived xenografts', Nature reviews. Cancer, vol. 17, nr. 4, blz. 254-268. https://doi.org/10.1038/nrc.2016.140

TY - JOUR

T1 - Interrogating open issues in cancer precision medicine with patient-derived xenografts

AU - Byrne, Annette T

AU - Alférez, Denis G

AU - Amant, Frédéric

AU - Annibali, Daniela

AU - Arribas, Joaquín

AU - Biankin, Andrew V

AU - Bruna, Alejandra

AU - Budinská, Eva

AU - Caldas, Carlos

AU - Chang, David K

AU - Clarke, Robert B

AU - Clevers, Hans

AU - Coukos, George

AU - Dangles-Marie, Virginie

AU - Eckhardt, S Gail

AU - Gonzalez-Suarez, Eva

AU - Hermans, Els

AU - Hidalgo, Manuel

AU - Jarzabek, Monika A

AU - de Jong, Steven

AU - Jonkers, Jos

AU - Kemper, Kristel

AU - Lanfrancone, Luisa

AU - Mælandsmo, Gunhild Mari

AU - Marangoni, Elisabetta

AU - Marine, Jean-Christophe

AU - Medico, Enzo

AU - Norum, Jens Henrik

AU - Palmer, Héctor G

AU - Peeper, Daniel S

AU - Pelicci, Pier Giuseppe

AU - Piris-Gimenez, Alejandro

AU - Roman-Roman, Sergio

AU - Rueda, Oscar M

AU - Seoane, Joan

AU - Serra, Violeta

AU - Soucek, Laura

AU - Vanhecke, Dominique

AU - Villanueva, Alberto

AU - Vinolo, Emilie

AU - Bertotti, Andrea

AU - Trusolino, Livio

PY - 2017/4

Y1 - 2017/4

N2 - Patient-derived xenografts (PDXs) have emerged as an important platform to elucidate new treatments and biomarkers in oncology. PDX models are used to address clinically relevant questions, including the contribution of tumour heterogeneity to therapeutic responsiveness, the patterns of cancer evolutionary dynamics during tumour progression and under drug pressure, and the mechanisms of resistance to treatment. The ability of PDX models to predict clinical outcomes is being improved through mouse humanization strategies and the implementation of co-clinical trials, within which patients and PDXs reciprocally inform therapeutic decisions. This Opinion article discusses aspects of PDX modelling that are relevant to these questions and highlights the merits of shared PDX resources to advance cancer medicine from the perspective of EurOPDX, an international initiative devoted to PDX-based research.

AB - Patient-derived xenografts (PDXs) have emerged as an important platform to elucidate new treatments and biomarkers in oncology. PDX models are used to address clinically relevant questions, including the contribution of tumour heterogeneity to therapeutic responsiveness, the patterns of cancer evolutionary dynamics during tumour progression and under drug pressure, and the mechanisms of resistance to treatment. The ability of PDX models to predict clinical outcomes is being improved through mouse humanization strategies and the implementation of co-clinical trials, within which patients and PDXs reciprocally inform therapeutic decisions. This Opinion article discusses aspects of PDX modelling that are relevant to these questions and highlights the merits of shared PDX resources to advance cancer medicine from the perspective of EurOPDX, an international initiative devoted to PDX-based research.

KW - Animals

KW - Biomarkers, Tumor

KW - Clinical Trials as Topic

KW - Disease Models, Animal

KW - Drug Resistance, Neoplasm

KW - Humans

KW - Immunotherapy

KW - Mice

KW - Neoplasm Metastasis

KW - Neoplasms

KW - Neoplastic Stem Cells

KW - Precision Medicine

KW - Xenograft Model Antitumor Assays

KW - Journal Article

KW - Review

KW - Research Support, Non-U.S. Gov't

KW - Research Support, N.I.H., Extramural

U2 - 10.1038/nrc.2016.140

DO - 10.1038/nrc.2016.140

M3 - Article

C2 - 28104906

SN - 1474-175X

VL - 17

SP - 254

EP - 268

JO - Nature reviews. Cancer

JF - Nature reviews. Cancer

IS - 4

ER -

Interrogating open issues in cancer precision medicine with patient-derived xenografts

Samenvatting

Toegang tot document

Vingerafdruk

Citeer dit